This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has signed a Letter of Intent with anti-aging, health and wellness company, Doctors Optimal Formula LLC, to create Retinalyze, LLC, an equally owned joint venture, to develop the first SVM-based retinal image analysis for retinal disease assessment and treatment protocols. Designed to assist physicians, the first product "Retinalyze Analytics Software" will use state-of-the-art mathematical algorithms and image-based pattern recognition technology to capture and analyze eye diseases such as age-related macular degeneration (AMD), the leading cause of blindness in adults 55 years and older.
“With Health Discovery’s SVM technology having been successfully applied to digital pathology and radiology in various applications, we are excited to develop Retinalize Analytics, with the expertise provided by the Doctors Optimal Formula’s Ophthalmology experts, to be able to address the needs of the potentially billion people throughout the world with life altering retinal diseases such as macular degeneration,” explains Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation.
AMD Alliance International reports the worldwide cost of visual impairment due to AMD alone at $343 billion, including $255 billion in direct health care costs. In North America alone, the associated health costs of AMD is near $98 billion. Even more importantly, these costs are set to rise dramatically through 2020 unless effective prevention and treatment strategies are adopted worldwide.
“Retinalyze Analytics will help physicians better "see" retina associated diseases, thereby providing a more accurate diagnostic interpretation of the images analyzed. With more than 400,000 optometrists, ophthalmologists and primary care providers testing and diagnosing such diseases in the U.S. alone, Retinalyze Analytics has the potential to become THE industry-changing standard for retinal testing,” explains Howard Loff, M.D., a leading oculoplastic surgeon and CEO and founder of Doctors Optimal Formula LLC. “We have great confidence that the SVM technology guided by HDC's expertise can successfully assist physicians with improvement in the interpretation of retinal images that are currently part of standard ophthalmologic exams. Beginning at age 40, it is recommended that all adults be screened for eye disease every two years unless there are indications requiring more frequent screening. Additionally, our proprietary technology will store images and assist in the early detection of any changes thereby optimizing a physician's diagnosis allowing early treatment to prevent vision loss, blindness, disability and premature death.”